Overview
RDI is a contract research organization that focuses exclusively on the in-vitro diagnostics (IVD) market, providing end-to-end clinical development and validation services for IVD products. It operates a high-complexity CLIA lab and a network of clinical sites to source samples, run testing across multiple platforms, and compile data for FDA submissions, supported by a paperless trial system called Diagnostica. Its differentiators are its singular focus on IVD, an integrated development-to-submission pathway, and validated quality credentials such as CLIA certification and CAP accreditation, plus a proprietary trial management tool. Its goal is to simplify and speed the process for diagnostics developers to attain timely FDA clearance or approval.
Work here?Claim your company
Simplify's take
What believers are saying
- 2026 job posts show active hiring for CLS, CRA, and engineering roles.
- RDI claims hundreds of diagnostic trials since 2008, proving repeat demand.
- CLIA certification in 2023 and CAP accreditation in 2024 strengthen sponsor credibility.
What critics are saying
- RDI’s small 11-50 headcount limits scalability versus IQVIA, ICON, and PPD.
- Van Nuys on-site hiring in 2026 signals labor intensity and weak automation maturity.
- A single FDA data-integrity failure could destroy sponsor trust and shut the business.
What makes RDI unique
- RDI runs IVD trials end-to-end with its own CLIA-CAP lab, 2024.
- Diagnostica unifies study operations, data, and regulatory workflows into one system.
- RDI’s 2008 IVD-only focus beats general CROs on diagnostics-specific execution.
Help us improve and share your feedback! Did you find this helpful?